Recap: Abeona Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Abeona Therapeutics (NASDAQ:ABEO) reported Q3 earnings, beating estimates with an EPS of $-0.48 compared to the forecasted $-0.52. However, revenue was unchanged from the same period last year. In the previous quarter, ABEO missed EPS estimates by $0.24, which resulted in a slight share price increase the following day.
November 13, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abeona Therapeutics reported better-than-expected Q3 earnings with an EPS of $-0.48, surpassing the estimate by 7.69%. However, the company's revenue remained flat compared to the same period last year.
Beating earnings estimates typically has a positive effect on stock prices in the short term, suggesting a potential increase for ABEO. However, the lack of revenue growth may temper investor enthusiasm, limiting the upside potential. Historical data from the previous quarter shows a slight increase in share price following an earnings miss, indicating that the market may react positively to the earnings beat despite flat revenues.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100